The Biosimilar Advantage: Powering patient access and industrial resilience

7 May 2026

EU policies must not push essential medicines off market: new Medicines for Europe president

9 February 2026

President Steffen Saltofte argues that EU policy must protect timely […]

‘Access Is A Right, Not A Privilege’ – Medicines For Europe’s Saltofte Sets Out Priorities

9 February 2026

The president of Medicines for Europe, Steffen Saltofte, says Medicines […]

The EU Biosimilar industry, which is central to competitiveness, needs Ambitious, Coherent, & Competition-Driven Biotech Policies

17 December 2025

Europe’s antibiotic shortages are a policy failure requiring urgent reform

8 December 2025

Europe faces chronic antibiotic shortages driven by rising production costs […]

Open Letter to COREPER: Council’s homeopathic approach to Critical Medicines Act will succeed – in watering down EU health security

24 September 2025

Generic medicine Industry join calls for an urgent pause to the extended producer responsibility scheme for urban wastewater to avert a healthcare crisis.

16 September 2025

The president of Medicines for Europe talks about the need […]

SANT Committee prioritises manufacturing competitiveness in draft report on the Critical Medicines Act

1 September 2025

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

5 August 2025

The president of Medicines for Europe talks about what the […]

Medicines for Europe intervenes in legal challenge against Urban Wastewater Treatment Directive’s EPR scheme

10 July 2025